Commentary on “Complement C3 vs C5 inhibition in severe COVID-19 [Carta]: early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al. (2021)
- Authors:
- USP affiliated authors: SANTOS, ISABEL KINNEY FERREIRA DE MIRANDA - FMRP ; CARDOSO, CRISTINA RIBEIRO DE BARROS - FCFRP
- Unidades: FMRP; FCFRP
- DOI: 10.1016/j.clim.2020.108618
- Subjects: COVID-19; ATIVAÇÃO DE COMPLEMENTO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Maryland Heights
- Date published: 2021
- Source:
- Título do periódico: Clinical Immunology
- ISSN: 1521-6616
- Volume/Número/Paginação/Ano: v. 222, art. 108618, 2021
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
SANTOS, Isabel Kinney Ferreira de Miranda e CARDOSO, Cristina Ribeiro de Barros. Commentary on “Complement C3 vs C5 inhibition in severe COVID-19 [Carta]: early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al. Clinical Immunology. Maryland Heights: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.clim.2020.108618. Acesso em: 28 mar. 2024. , 2021 -
APA
Santos, I. K. F. de M., & Cardoso, C. R. de B. (2021). Commentary on “Complement C3 vs C5 inhibition in severe COVID-19 [Carta]: early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al. Clinical Immunology. Maryland Heights: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.clim.2020.108618 -
NLM
Santos IKF de M, Cardoso CR de B. Commentary on “Complement C3 vs C5 inhibition in severe COVID-19 [Carta]: early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al. [Internet]. Clinical Immunology. 2021 ; 222[citado 2024 mar. 28 ] Available from: https://doi.org/10.1016/j.clim.2020.108618 -
Vancouver
Santos IKF de M, Cardoso CR de B. Commentary on “Complement C3 vs C5 inhibition in severe COVID-19 [Carta]: early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al. [Internet]. Clinical Immunology. 2021 ; 222[citado 2024 mar. 28 ] Available from: https://doi.org/10.1016/j.clim.2020.108618 - What happens in Brazil? A pandemic of misinformation that culminates in an endless disease burden [Carta]
- RNA-SEQ analysis of bovine leukocytes for identification of molecular signatures associated to a protective anti-tick immunity conferred by a multicomponent anti-tick vaccine
- Length and density of filiform tongue papillae: differences between tick-susceptible and resistant cattle may affect tick loads
- Modulação da resposta imune por antígenos alimentares: caracterização de um novo modelo de inflamação intestinal crônica
- Modulação da resposta imune de mucosas
- Toll-like receptor 10 controls TLR2-induced cytokine production in monocytes from patients with Parkinson's disease
- Selective serotonin reuptake inhibitors attenuate the antigen presentation from dendritic cells to effector T lymphocytes
- Editorial: intestinal dysbiosis in inflammatory diseases [Editorial]
- Impact of hydroxychloroquine on antibody responses to the SARS-CoV-2 coronavirus [Carta]
- Complete coding genome sequence for mogiana tick virus, a jingmenvirus isolated from ticks in Brazil
Informações sobre o DOI: 10.1016/j.clim.2020.108618 (Fonte: oaDOI API)
Download do texto completo
Tipo | Nome | Link | |
---|---|---|---|
003020938.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas